Microbix Biosystems Inc. (TSE:MBX) Director Bo Hollas Sells 100,000 Shares

Microbix Biosystems Inc. (TSE:MBXGet Free Report) Director Bo Hollas sold 100,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of C$0.39, for a total value of C$39,250.00.

Microbix Biosystems Stock Down 2.6 %

MBX opened at C$0.38 on Wednesday. The company has a debt-to-equity ratio of 24.53, a current ratio of 8.53 and a quick ratio of 5.57. The business has a 50 day simple moving average of C$0.40 and a 200-day simple moving average of C$0.34. The stock has a market capitalization of C$51.89 million, a P/E ratio of 12.67 and a beta of 0.28. Microbix Biosystems Inc. has a 12 month low of C$0.23 and a 12 month high of C$0.47.

Microbix Biosystems (TSE:MBXGet Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The company reported C$0.02 EPS for the quarter. The business had revenue of C$8.41 million during the quarter, compared to analysts’ expectations of C$8.10 million. Microbix Biosystems had a return on equity of 14.66% and a net margin of 16.57%. On average, equities analysts anticipate that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Bloom Burton reissued a “buy” rating on shares of Microbix Biosystems in a report on Thursday, January 4th.

Read Our Latest Stock Analysis on MBX

Microbix Biosystems Company Profile

(Get Free Report)

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.

Featured Articles

Receive News & Ratings for Microbix Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbix Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.